MedPath

Dabigatran

Generic Name
Dabigatran
Brand Names
Dabigatran Etexilate Leon Farma, Dabigatran Etexilate Accord, Pradaxa
Drug Type
Small Molecule
Chemical Formula
C25H25N7O3
CAS Number
211914-51-1
Unique Ingredient Identifier
I0VM4M70GC

Overview

Dabigatran is the active form of the orally bioavailable prodrug dabigatran etexilate.

Background

Dabigatran is the active form of the orally bioavailable prodrug dabigatran etexilate.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

View More Clinical Trials

Sign in to access the complete clinical trial database with detailed study information.

Title
Posted
Study ID
Phase
Status
Sponsor
Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S
2016/05/11
NCT02769078
N/A
Completed
Bristol-Myers Squibb
Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants
2016/04/28
NCT02754154
N/A
Completed
Bristol-Myers Squibb
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
2016/04/20
NCT02744092
Not Applicable
Completed
Alliance Foundation Trials, LLC.
Dabigatran Study in the Early Phase of Stroke. New Neuroimaging Markers and Biomarkers Study (SEDMAN STUDY)
2016/04/19
NCT02742480
N/A
UNKNOWN
Hospital Mutua de Terrassa
COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials
2016/03/31
NCT02723981
Phase 4
Withdrawn
IHF GmbH - Institut für Herzinfarktforschung
Bioavailability Study of Five Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects
2016/03/17
NCT02710630
Phase 1
Completed
Boehringer Ingelheim
Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist
2016/02/22
NCT02687867
N/A
Completed
Bayer
APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study
2015/12/28
NCT02640222
N/A
Completed
Bristol-Myers Squibb
Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan
2015/12/15
NCT02631057
N/A
Completed
Boehringer Ingelheim
Atrial Fibrillation Patient Preference Study
2015/11/23
NCT02611635
N/A
Completed
Bayer

FDA Drug Approvals

View More FDA Approvals

Sign in to access additional FDA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

View More EMA Approvals

Sign in to access additional EMA-approved drug information with detailed regulatory data.

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

View More HSA Approvals

Sign in to access additional HSA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

View More NMPA Approvals

Sign in to access additional NMPA-approved drug information with detailed regulatory data.

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

View More PPB Approvals

Sign in to access additional PPB-approved drug information with detailed regulatory data.

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

View More TGA Approvals

Sign in to access additional TGA-approved drug information with detailed regulatory data.

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy